Solid Biosciences files $200 million at-the-market stock offering with Jefferies

Solid Biosciences Inc. filed a prospectus supplement dated August 6, 2026 covering an at-the-market equity offering of up to $200,000,000 in common stock, sold through a sales agreement with Jefferies LLC originally dated March 13, 2019, which was amended and restated on March 13, 2024.¹

The new filing replaces an earlier prospectus supplement dated May 15, 2025, which had covered the offering and sale of shares having an aggregate offering price of up to $85,000,000 through Jefferies.¹ As of the date of the new filing, the company had issued and sold shares for aggregate gross sale proceeds of approximately $84,993,553 pursuant to the sales agreement and the prior prospectus supplement, with $6,447 remaining unsold under the prior supplement.¹ That leftover unsold balance will no longer be offered under the prior supplement, but will instead be offered under the new supplement, joining an additional $199,993,553 in shares to be offered under the new supplement.¹

Jefferies is entitled to compensation at a commission rate of up to 3.0% of the gross sales price of the shares sold under the sales agreement.¹ Solid Biosciences stock last traded at $8.73 per share on August 5, 2026, as reported on The Nasdaq Global Select Market.¹

Assuming sales of 22,909,507 shares at that $8.73 price, the company could have up to 128,034,873 shares outstanding immediately after the offering.¹ At that assumed price, the company's as-adjusted net tangible book value as of June 30, 2026 would have been approximately $567.8 million, or about $4.43 per share, representing an immediate increase of approximately $0.87 per share for existing stockholders and an immediate dilution of approximately $4.30 per share for purchasers in this offering.¹

The company said it intends to use net proceeds for general corporate purposes, potentially including research and development costs, preclinical and clinical development, the acquisition or in-license of products, product candidates, companies, businesses or technologies, repayment and refinancing of debt, and working capital and capital expenditures.¹ Its pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.¹